SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) antibody
-
- Target See all SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) Antibodies
- SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)
-
Reactivity
- SARS Coronavirus (SARS-CoV)
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Un-conjugated
-
Application
- ELISA, Western Blotting (WB), Immunofluorescence (IF)
- Purpose
- Mouse monoclonal SARS Coronavirus antibody
- Specificity
- This antibody recognizes the nucleoprotein of the SARS virus
- Purification
- Protein A chromatography purified IgG fraction
- Purity
- > 90 %
- Immunogen
- SARS coronavirus antibody was raised in mouse using nucleoprotein of the SARS virus as the immunogen.
- Clone
- M88095
- Isotype
- IgG1
- Top Product
- Discover our top product SARS-CoV N Primary Antibody
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Comment
-
This SARS-CoV Nucleocapside antibody reacts with SARS-CoV protein (ABIN6952561).
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- 10 mM PBS, pH 7.4 with 0.1 % Sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- -20°C
-
- Target
- SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)
- Alternative Name
- SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N Products)
- Synonyms
- NC antibody, Protein N antibody, nucleocapsid protein antibody, N antibody
- Target Type
- Viral Protein
- Background
- The SARS coronavirus, sometimes shortened to SARS-CoV, is the virus that causes severe acute respiratory syndrome (SARS). On April 16, 2003, following the outbreak of SARS in Asia and secondary cases elsewhere in the world, the World Health Organization (WHO) issued a press release stating that the coronavirus identified by a number of laboratories was the official cause of SARS. Samples of the virus are being held in laboratories in New York, San Francisco, Manila, Hong Kong, and Toronto.
-